Rheumatology Advance Access originally published online on February 3, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2004; 43: 592-595
Rheumatology Vol. 43 No. 5 (c) British Society for Rheumatology 2004; all rights reserved
Clinical |
Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing
Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 1Institution of Civic Medicine, Department of General Medicine, University Hospital, Malmö, University of Lund, Lund, Sweden, 2Medicine, University Hospital of Tampere, Tampere, Finland and 3Pfizer ApS, Ballerup, Denmark.
Correspondence to: K. Stengaard-Pedersen, Department of Rheumatology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark. E-mail: stengaard{at}akh.aaa.dk
Objectives. The primary objective was to demonstrate equivalence between a.m. and p.m. dosing of celecoxib 200 mg q.d. An equivalence assessment of q.d. vs b.i.d. dosing was a secondary objective.
Methods. In this randomized, double-blind study, patients with symptomatic osteoarthritis of the knee or hip were randomized to receive celecoxib 200 mg q.d. a.m., celecoxib 200 mg q.d. p.m. or celecoxib 100 mg b.i.d. The primary outcome variable, measured at week 12 on a 0- to 10-point integrated scale, was patient satisfaction assessment (pain relief, walking/bending, and willingness to continue medication). Equivalence was declared if the 95% confidence interval (CI) of the difference (a.m. q.d. vs p.m. q.d., b.i.d. vs q.d.) fell within the interval of –2 to +2.
Results. A total of 697 patients were enrolled in this trial. For the a.m. vs p.m. comparison, the 95% CIs were within the prespecified equivalence criteria for all three measures of patient satisfaction: pain relief, mean –0.2, 95% CI –0.53 to 0.68; ability to walk and bend, mean –0.2, 95% CI –0.54 to 0.64; willingness to continue medication, mean –0.7, 95% CI –0.98 to 0.49. The 95% CIs for the q.d. vs b.i.d. comparison were also within the –2 to +2 interval.
Conclusion. Regardless of the time of day at which celecoxib 200 mg q.d. is administered, patients are equally satisfied with the pain relief, ability to walk and bend, and willingness to continue medication.
KEY WORDS: Osteoarthritis, COX-2 specific inhibitor, Celecoxib, Dose regimen.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y Yazici and H Yazici A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127. [Abstract] [Full Text] [PDF]
|
|